Vigilant Biosciences, Inc. Expands Executive Leadership Team and Board of Directors with Veteran Biotechnology and Diagnostics Executives

MIAMI, Feb. 17, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the expansion of its leadership team with the addition of Greg Stanley as its Vice President of Global Sales and Marketing and the appointment of Timothy C. Barabe to the Company's Board of Directors.

Mr. Stanley joins Vigilant Biosciences as an accomplished commercial executive with more than 25 years of experience in the biopharmaceutical and diagnostics industry. He most recently served as Vice President of Sales and Marketing for Global Diagnostics Business Unit OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company.  Prior to his position at OPKO Health, Inc., Mr. Stanley spent seven years as Chief Commercial Officer at Oncimmune, an oncology company focused on the early detection of cancer. Previously, from 2001 to 2006, Mr. Stanley was Director of Marketing and National Director of Corporate Accounts at Roche Diagnostics.

Mr. Stanley began his career at Abbott Laboratories, and went on to hold a series of positions with increasing responsibility at various diagnostics and biotechnology companies including Chiron and Radiometer before joining Roche Diagnostics in 2001.

Mr. Stanley received his B.S. from the University of Missouri-Saint Louis.

"We are delighted that Greg has joined Vigilant Biosciences to lead our Global Sales and Marketing team," said Matthew Kim, founder and Chief Executive Officer of Vigilant Biosciences, Inc. "Greg brings a tremendous depth of experience in the biotechnology and diagnostics business in both domestic and international markets. He is a proven sales and marketing executive, and as we prepare our OncAlert products for commercialization, his expertise will be beneficial to ensuring a successful international and domestic launch."

Mr. Barabe has enjoyed a distinguished career in the life sciences and pharmaceutical industries. He most recently served as Executive Vice President and Chief Financial Officer of Affymetrix, Inc., a pioneer in microarray technology and a leader in genomics analysis. He retired from the position in June 2013. Previously, from July 2006 until March 2010, he was Senior Vice President and Chief Financial Officer of Human Genome Sciences, Inc. Prior to Human Genome Sciences, Mr. Barabe was with Regent Medical Limited, a U.K.-based, privately owned, surgical supply company, where he was Chief Financial Officer, from 2004 to 2006. 

Mr. Barabe began his career at Novartis AG where from 1982 through August 2004 he held a succession of senior executive positions in finance and general management, most recently as the Chief Financial Officer of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis. In addition to Vigilant, Mr. Barabe serves on the Board of Directors for Opexa Therapeutics, Inc., a biopharmaceutical company developing personalized immunotherapy for multiple scleroris, and ArQule, Inc., a clinically-staged cancer therapeutic company.

Mr. Barabe received his B.B.A. degree from the University of Massachusetts (Amherst) and his M.B.A. degree from the University of Chicago.

"We are thrilled to welcome Tim, a seasoned life sciences executive, to our Board of Directors," said Matthew Kim, founder and Chief Executive Officer of Vigilant Biosciences, Inc. "His strategic leadership experience across a variety of companies in the life sciences space will bring additional perspective and expertise to our Board. His experience will be valuable as we continue to advance our oral cancer risk assessment system towards commercialization."

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are accurate, effective and affordable, empowering healthcare practitioners to easily assess the risk of oral cancer early, and improve outcomes through earlier intervention. Vigilant Biosciences' OncAlert Oral Cancer Risk Assessment System's point-of-care and lab assay products are both currently undergoing the CE Mark registration approval process. For more information, visit www.vigilantbiosciences.com.

Logo - http://photos.prnewswire.com/prnh/20141210/163560LOGO

SOURCE Vigilant Biosciences, Inc.

Related Links

http://www.vigilantbiosciences.com